Analyst Consensus ?
ConsensusHold38 ratings
Bullish1436.9%
Neutral2360.5%
Bearish12.6%
1 unmapped firm rating excluded from the percentages.
Pfizer Inc. · PFE · FY2026 Q1 · Calendar Q2 2026
Pfizer Q1 2026: Revenue and EPS Beat, Guidance Reaffirmed, Pipeline Advances
Pfizer's Q1 2026 results show the post-COVID turnaround continuing to build momentum. Revenue of $14.5B and adjusted EPS of $0.75 both exceeded consensus, driven by 22% operational growth in the launched and acquired portfolio led by Padcev, Nurtec, Eliquis, and Vyndamax. Legal settlements extending Vyndamax exclusivity to mid-2029 and a Belgian court ruling on Comirnaty improve cash-flow visibility and support a high-single-digit CAGR starting 2029. Management reaffirmed full-year guidance and highlighted roughly 20 pivotal study starts, 8 key readouts, and 4 regulatory decisions planned for 2026. Despite the beat, the stock saw a modest negative abnormal return on report day and has drifted approximately 4.2% lower subsequently, suggesting the market remains cautious about LOE pressures through 2028 and the 2028 timeline for the first obesity approval.
Reported Before market openNYSEHealthcare
$140.61B market cap
100quality score
Company context
Snapshot as of publicationPfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid.…
Earnings scorecard
Reported versus consensus
Reported EPS
$0.75
Consensus $1
EPS surprise
+3.9%
Reported versus consensus
Reported revenue
$14.45B
Consensus $13.84B
Revenue surprise
+4.4%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$25.25Current
$20Low
$39.24Average
$70High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 28, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Guggenheim | Buy | Buy | Maintain | Jul 13, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Jul 10, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 8, 2026 |
| HSBC | Hold | Buy | Downgrade | Jul 6, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 6, 2026 |
| RBC Capital | Sector Perform | Underperform | Upgrade | Jun 10, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Apr 29, 2026 |
| UBS | Neutral | Neutral | Maintain | Apr 13, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 10, 2026 |
| Argus Research | Buy | Hold | Upgrade | Mar 2, 2026 |
| Freedom Broker | Buy | Buy | Maintain | Feb 9, 2026 |
| Goldman Sachs | Neutral | Buy | Downgrade | Apr 8, 2025 |
| Truist Securities | Buy | Buy | Maintain | Dec 18, 2024 |
| Daiwa Capital | Outperform | Neutral | Upgrade | Aug 8, 2024 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2024 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 31, 2024 |
| TD Cowen | Market Perform | Outperform | Downgrade | Jan 4, 2024 |
| Jefferies | Buy | Hold | Upgrade | Oct 16, 2023 |
| Credit Suisse | Neutral | Outperform | Downgrade | Jun 29, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Feb 1, 2023 |
| Atlantic Equities | Neutral | Neutral | Maintain | Feb 1, 2023 |
| Mizuho | Neutral | Neutral | Maintain | Dec 14, 2021 |
| DZ Bank | Buy | Hold | Upgrade | Feb 4, 2021 |
| Bernstein | Perform | Market Perform | Maintain | Nov 10, 2020 |
| Berenberg | Hold | Hold | Maintain | Sep 29, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Jul 30, 2019 |
| Argus | Outperform | Neutral | Upgrade | Jan 31, 2019 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Jan 31, 2018 |
| Societe Generale | Hold | Hold | Maintain | Apr 6, 2016 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Feb 16, 2016 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Oct 20, 2015 |
| PiperJaffray | Overweight | Overweight | Maintain | Jun 17, 2015 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 28, 2015 |
| LBBW Research | Buy | Hold | Upgrade | Nov 14, 2013 |
| Standpoint Research | Sell | Hold | Downgrade | Jul 2, 2013 |
| Hilliard Lyons | Long Term Buy | Maintain | Jan 29, 2013 | |
| MKM Partners | Neutral | Buy | Downgrade | Nov 27, 2012 |
| ISI Group | Buy | Buy | Maintain | Apr 9, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $25.25. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| HSBC | Analyst unavailable | $28 | $24.32 | +10.9% | Jul 6, 2026 |
| UBS | Michael Yee | $27 | $26.34 | +6.9% | May 27, 2026 |
| Wolfe Research | Alexandria Hammond | $26 | $25.96 | +3.0% | May 14, 2026 |
| Morgan Stanley | Terence Flynn | $27 | $27.06 | +6.9% | Mar 17, 2026 |
| BMO Capital | Evan David Seigerman | $30 | $26.48 | +18.8% | Mar 9, 2026 |
| RBC Capital | Trung Huynh | $25 | $27.14 | -1.0% | Feb 24, 2026 |
| Barclays | Emily Field | $25 | $26.86 | -1.0% | Feb 19, 2026 |
| Daiwa | Narumi Nakagiri | $27 | $27.73 | +6.9% | Feb 12, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $27 | $25.88 | +6.9% | Jan 27, 2026 |
| UBS | Analyst unavailable | $25 | $25.43 | -1.0% | Jan 6, 2026 |
| Wolfe Research | Alexandria Hammond | $24 | $25.53 | -5.0% | Dec 17, 2025 |
| Morgan Stanley | Analyst unavailable | $28 | $25.89 | +10.9% | Dec 12, 2025 |
| HSBC | Rajesh Kumar | $29 | $25.33 | +14.9% | Dec 10, 2025 |
| Guggenheim | Analyst unavailable | $35 | $25.17 | +38.6% | Nov 24, 2025 |
| Goldman Sachs | Asad Haider | $26 | $24.22 | +3.0% | Nov 5, 2025 |
| Bernstein | Courtney Breen | $30 | $24.45 | +18.8% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $32 | $25.24 | +26.7% | Oct 10, 2025 |
| UBS | Tim Anderson | $28 | $27.16 | +10.9% | Oct 1, 2025 |
| Cantor Fitzgerald | Carter Gould | $24 | $22.53 | -5.0% | Apr 22, 2025 |
| Truist Financial | Robyn Karnauskas | $32 | $25.89 | +26.7% | Dec 18, 2024 |
| Goldman Sachs | Chris Shibutani | $33 | $28.46 | +30.7% | Oct 30, 2024 |
| Bernstein | Courtney Breen | $32 | $29.67 | +26.7% | Oct 17, 2024 |
| Barclays | Carter Gould | $32 | $28.93 | +26.7% | Sep 25, 2024 |
| Daiwa | Narumi Nakagiri | $34 | $28.85 | +34.7% | Aug 7, 2024 |
| Wells Fargo | Mohit Bansal | $30 | $31.39 | +18.8% | Jul 31, 2024 |
| Goldman Sachs | Chris Shibutani | $34 | $31.39 | +34.7% | Jul 31, 2024 |
| Guggenheim | Vamil Divan | $36 | $30.72 | +42.6% | Jul 30, 2024 |
| Barclays | Carter Gould | $30 | $27.72 | +18.8% | Jul 10, 2024 |
| BMO Capital | Evan Seigerman | $36 | $29.6 | +42.6% | May 22, 2024 |
| Cantor Fitzgerald | Louise Chen | $45 | $26.97 | +78.2% | Feb 14, 2024 |
| Morgan Stanley | Thomas Yeh | $20 | $26.92 | -20.8% | Dec 14, 2023 |
| Morgan Stanley | Terence Flynn | $37 | $30.5 | +46.5% | Nov 27, 2023 |
| Morgan Stanley | Analyst unavailable | $45 | $43.84 | +78.2% | Feb 1, 2023 |
| Credit Suisse | Analyst unavailable | $50 | $43.59 | +98.0% | Feb 1, 2023 |
| Barclays | Analyst unavailable | $44 | $44.16 | +74.3% | Feb 1, 2023 |
| Atlantic Equities | Analyst unavailable | $46 | $44.16 | +82.2% | Feb 1, 2023 |
| Leerink Partners | Analyst unavailable | $48 | $44.16 | +90.1% | Feb 1, 2023 |
| Morgan Stanley | Analyst unavailable | $53 | $54.73 | +109.9% | Dec 14, 2022 |
| Goldman Sachs | Chris Shibutani | $60 | $53.37 | +137.6% | Dec 13, 2022 |
| Credit Suisse | Analyst unavailable | $55 | $48.33 | +117.8% | Nov 18, 2022 |
| Leerink Partners | David Risinger | $55 | $52.88 | +117.8% | May 23, 2022 |
| Wells Fargo | Mohit Bansal | $54.42 | $19.11 | +115.5% | May 10, 2022 |
| Wells Fargo | Mohit Bansal | $55 | $49.04 | +117.8% | May 9, 2022 |
| Morgan Stanley | Analyst unavailable | $52 | $49.68 | +105.9% | May 4, 2022 |
| Mizuho Securities | Vamil Divan | $55 | $49.07 | +117.8% | May 2, 2022 |
| Cantor Fitzgerald | Louise Chen | $75 | $53.12 | +197.0% | Apr 15, 2022 |
| Morgan Stanley | Terrance Flynn | $55 | $55.17 | +117.8% | Apr 10, 2022 |
| Citigroup | Andrew Baum | $57 | $55.17 | +125.7% | Apr 9, 2022 |
| Bank of America Securities | Geoff Meacham | $70 | $50.27 | +177.2% | Mar 12, 2022 |
| Barclays | Carter Gould | $54 | $51.7 | +113.9% | Feb 8, 2022 |
| Goldman Sachs | Chris Shibutani | $50 | $51.7 | +98.0% | Feb 8, 2022 |
| J.P. Morgan | Chris Schott | $57 | $51.7 | +125.7% | Feb 8, 2022 |
| BMO Capital | Evan Seigerman | $76 | $54.95 | +201.0% | Jan 15, 2022 |
| Bernstein | Aaron Gal | $65 | $56.22 | +157.4% | Jan 3, 2022 |
| Leerink Partners | Geoff Porges | $56 | $59.1 | +121.8% | Dec 22, 2021 |
| UBS | Colin Bristow | $60 | $54.78 | +137.6% | Dec 13, 2021 |
| Independent Research | Tobias Gottschalt | $54 | $49.8 | +113.9% | Nov 11, 2021 |
| Wolfe Research | Tim Anderson | $46 | $44.09 | +82.2% | Nov 3, 2021 |
| RBC Capital | Daniel Busby | $44 | $42.1 | +74.3% | Jul 29, 2021 |
| Argus Research | David Toung | $55 | $37.54 | +117.8% | Jun 1, 2021 |
Track every rating change on PFE the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
+0.6%
Event window
SPY move
+0.8%
Same window
Abnormal move
-0.2%
Stock minus SPY
Volume
1.7×
Versus trailing sessions
Subsequent drift
-4.2%
Up to 20 sessions
PFESPY benchmark
Follow PFE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Revenue of $14.5B beat the $13.84B estimate by 4.4%; adjusted EPS of $0.75 beat the $0.722 estimate by 3.9%. The launched and acquired portfolio contributed $3.1B, growing 22% operationally. A Vyndamax patent settlement extends exclusivity to mid-2029, reshaping post-2028 revenue outlook. Phase III EV-304 data showed approximately 50% reduction in recurrence or death for muscle-invasive bladder cancer with Padcev plus pembrolizumab. Ecnoglutide launched in China via partnership with Hangzhou Sciwind Biosciences. A Belgian court ruling on Comirnaty contracts and the Vyndamax settlement both improve cash-flow outlook. Full-year 2026 guidance was reaffirmed at $59.5–62.5B revenue and $2.80–3.00 adjusted EPS.
Guidance delta
2026 guidance was reaffirmed at $59.5–62.5B revenue and $2.80–3.00 adjusted EPS, unchanged from the prior quarter's outlook. Management tone remained confident. The dividend was maintained. No changes to the capital allocation framework were announced.
Key takeaways
- Q1 revenue of $14.5B and adjusted EPS of $0.75 both beat consensus, with the launched/acquired portfolio growing 22% operationally to $3.1B.
- Vyndamax patent settlement extends exclusivity to mid-2029, improving post-2028 revenue trajectory and supporting a high-single-digit CAGR starting 2029.
- Phase III EV-304 data showed approximately 50% reduction in recurrence or death for muscle-invasive bladder cancer with Padcev plus pembrolizumab.
- Pipeline momentum includes roughly 20 pivotal study starts, 8 key readouts, and 4 regulatory decisions planned for 2026.
- Full-year 2026 guidance reaffirmed at $59.5–62.5B revenue and $2.80–3.00 adjusted EPS; dividend maintained.
Management priorities
- Advance 10 Phase III studies and target first obesity approval in 2028
- Further integrate Seagen assets and expand the ADC oncology platform
- Launch 25-valent pediatric pneumococcal vaccine and fifth-generation adult vaccine covering 35 serotypes
- Deploy AI across R&D, commercial, manufacturing, and enterprise functions
- Scale Metsera obesity portfolio globally, leveraging primary-care capabilities
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
- Polygon adjusted daily market bars · 2026-07-28T20:41:43.619399+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T20:41:43.616722+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.